Anti-fas IgM monoclonal antibody enhances apoptosis induced by low-dose cytosine arabinoside

Anticancer Research

Volumn 19, Issue 1 A, 1999, Pages 197-204

  Nakamura, Shinobu ^a   Takeshima, Minoru ^a   Nakamura, Yoshihisa ^a   Ohtake, Shigeki ^a   Matsuda, Tamotsu ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Apoptosis; Cytosine arabinoside; Fas; HL60 cells; Leukemia

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; FAS ANTIGEN; IMMUNOGLOBULIN M ANTIBODY; MONOCLONAL ANTIBODY;

ACUTE NONLYMPHOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CONTROLLED STUDY; ELECTROPHORESIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MORPHOLOGY; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD95; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CYTARABINE; DNA FRAGMENTATION; FLOW CYTOMETRY; HL-60 CELLS; HUMANS; IMMUNOGLOBULIN M;

EID: 0032897052     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Kaufmann SH: Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Cancer Res 49: 5870-5878, 1989.
2. Walker PR, Smith C, Youdale T, Leblanc J, Whitfield JF and Sikorska M: Topoisomerase II-reactive chemotherapeutic drugs induce apoptosis in thymocytes. Cancer Res 57: 1078-1085, 1991.
3. Gunji H, Kharbanda S and Kufe D: Induction of internucleosomal DNA fragmentation in human myeloid leukemia cells by 1-β-D-arabinofuranosylcytosine. Cancer Res 51: 741-743, 1991.
4. Lotem J and Sachs L: Hematopoietic cytokincs inhibit apoptosis by transforming growth factor β1 and cancer chemotherary compounds in myeloid leukemic cells. Blood 80: 1750-1757, 1992.
5. Eastman A: Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells 2: 275-280, 1990.
6. McGahon AJ, Pereira APC, Daly L and Cotter TG: Chemotherapeutic drug-induced apoptosis in human leukemic cells is independent of the Fas (APO-1/CD95) receptor/ligand system. Br J Haematol 101: 539-547, 1998.
7. Gorczyca W, Bigman K, Mittelman A, Ahmed T, Gong J, Melamed MR and Darzynkiewicz Z: Induction of DNA strand breaks associated with apoptosis during treatment of leukemias. Leukemia 7: 659-670, 1993.
8. Bhalla K, Tang C, Ibrado AM, Grant S, Tourkina E, Holladay C, Hughes M, Mahoney ME and Huang Y: Granulocyte-macrophage colony-stimulating factor / interleukin-3 fusion protein (pIXY 321) enhances high-dose ara-C-induced programmed cell death or apoptosis in human myeloid leukemia cells. Blood 80: 2883-2890, 1992.
9. Bouffard DY and Momparler RL: Comparison of the induction of apoptosis in human leukemic cell lines by 2′,2′-difluorodeoxycytidine (gemcitabine) and cytosine arabinoside. Leukemia Res 19: 849-856, 1995.
10. Van Prooijen HC, Dekker AW and Punt K: The use of intermediate dose cytosine arabinoside (ID Ara-C) in the treatment of acute non-lymphocytic leukaemia in relapse. Br J Haematol 57: 291-299, 1984.
11. Breihaupt H, Pralle H, Eckhardt T, Hattingberg M, Schick J and Löffier H: Clinical results and pharmacokinetics of high-dose cytosine arabinoside (HD Ara-C). Cancer 50: 1248-1257, 1982.
12. Bishop JF, Matthews JP, Young GA, Szer J, Gillet A, Joshua D, Bradstock K, Enno A, Wolf MM, Fox R, Cobcroft R, Herrmann R, Van Der Weyden M, Lowenthal RM, Page F, Garson OM and Juneja S: A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 87: 1710-1717, 1996.
13. Castaigne S, Daniel MT, Tilly H, Herait P and Degos L: Does treatment with ARA-C in low dosage cause differentiation of leukemic cells? Blood 62: 85-86, 1983.
14. Harris AL, Potter C, Bunch C, Boutagy J, Harvey DJ and Grahame-Smith DG: Pharmacokinetics of cytosine arabinoside in patients with acute myeloid leukaemia. Br J Clin Pharmacol 8: 219-227, 1979.
15. Spriggs D, Griffin J, Wisch J and Kufe D: Clinical pharmacology of low-dose cytosine arabinoside. Blood 65: 1087-1089, 1985.
16. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Hase A, Seto Y and Nagata S: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66: 233-243, 1991.
17. Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, Klas C, LiWeber M, Richrds S, Dhein J, Trauth BC, Ponsting H and Krammer PH: Purification and molecular cloning of the Apo-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. J Bio Chem 267: 10709-10715, 1992.
18. Yonehara S, Ishii A and Yonehara M: A cell-killing monoclonal antibody (ANTI-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 169: 1747-1756, 1989.
19. Suda T, Takahashi T, Golstein P and Nagata S: Moecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75: 1169-1178, 1993.
20. Maciejewski J, Selleri C, Anderson S and Young NS: Fas antigen expression on CD34 human marrow cells is induced by interferon gamma and tumor necrosis factor alfa and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood 85: 3183-3190, 1995.
21. Nagafuji K, Shibuya T, Harada M, Mizuno S, Takenaka K, Miyamoto T, Okamura T, Gondo H and Niho Y: Functional expression of Fas (CD95) on hematopoietic progenitor cells. Blood 86: 883-889, 1995.
22. Gersuk GM, Lee JW, Beckham CA, Anderson J and Deeg HJ: Fas (CD95) receptor and Fas-ligand expression in hone marrow cells from patients with myelodysplastic syndrome. Blood 88: 1122-1123, 1996.
23. Lennon SV, Martin SJ and Cotter TG: Dose-dependent induction of apoptosis in human tumor cell lines by widely diverging stimuli. Cell Prolif 24: 203-214, 1991.
24. Nakamura S, Takeshima M, Nakamura Y, Otake S and Matsuda T: Induction of apoptosis in HL60 leukemic cells by anticancer drugs in combination with anti-Fas monoclonal antibody. Anticancer Res 17: 173-180, 1997.
25. Telford WG, King LE and Fraker PJ: Comparative evaluation of several DNA binding dyes in the detection of apoptosis-associated chromatin degradation by flow cytometry. Cytometry 13: 137-143, 1992.
26. Craig RW, Frankfurt OS, Sakagami H, Takeda K and Bloch A: Macromolecular and cell cycle effects of different classes of agents inducing the maturation of human myeloblastic leukemia (ML-1) cells. Cancer Res 44: 2421-2429, 1984.
27. Griffin J, Munroe D, Major P and Kufe D: Induction of differentiation of human myeloid leukemia cells by inhibitors of DNA synthesis. Exp Hematol 10: 774-781, 1982.
28. Takenaka K, Nagafuji K, Harada M, Mizuno S, Miyamoto T, Makino S, Gondo H, Okamura T and Niho Y: In vitro expansion of hematopoietic progenitor cells induces functional expression of Fas antigen (CD95). Blood 88: 2871-2877, 1996.
29. Munker R, Lübbert M, Yonehara S, Tuchnitz A, Mertelsmann R and Wilmanns W: Expression of the Fas antigen on primary human leukemia cells. Ann Hematol 70: 15-17, 1995.